GenVec and its peers
1 companies side by side: each figure with its date and source, its rank in the group and its percentile in its sector and country.
Companies in the group
Up to 12. Remove or re-base from the table's column heads.
Keep this group
Save it for yourself or, in a team, for everyone in it.
Suggested peers of GenVec#
Companies of the same industry, within a hundred times its size (latest annual revenue), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Mereo BioPharma Group plcMREO · 🇺🇸 USASame industry: Biotechnology · Similar size: $0 M revenue against $1 M · Same country: USA · Ratios of the last two fiscal years on filerevenue $1 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- Lipella Pharmaceuticals Inc.LIPO · 🇺🇸 USASame industry: Biotechnology · Similar size: $1 M revenue against $1 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $6 M (last known, Jan 5, 2024) · revenue $1 M (year to December 2024)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- Yarrow Bioscience, Inc.YARW · 🇺🇸 USASame industry: Biotechnology · Similar size: $1 M revenue against $1 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $307 M (Oct 28, 2026) · revenue $1 M (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)+ Add
- Cardiff Oncology, Inc.CRDF · 🇺🇸 USASame industry: Biotechnology · Similar size: $1 M revenue against $1 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $71 M (Oct 30, 2026) · revenue $1 M (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)+ Add
- PMGC Holdings Inc.ELAB · 🇺🇸 USASame industry: Biotechnology · Similar size: $1 M revenue against $1 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $24 M (Oct 14, 2026) · revenue $1 M (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)+ Add
- Vaccinex, Inc.VCNX · 🇺🇸 USASame industry: Biotechnology · Similar size: $1 M revenue against $1 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $9 M (last known, Jan 5, 2024) · revenue $1 M (year to December 2024)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)+ Add
- MediciNova, Inc.MNOV · 🇺🇸 USASame industry: Biotechnology · Similar size: $0 M revenue against $1 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $74 M (Oct 16, 2026) · revenue $0 M (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)+ Add
- Bio Green Med Solution, Inc.BGMS · 🇺🇸 USASame industry: Biotechnology · Similar size: $1 M revenue against $1 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $6 M (Oct 26, 2026) · revenue $1 M (year to December 2025)98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)+ Add
- Provectus Biopharmaceuticals Inc.PVCT · 🇺🇸 USASame industry: Biotechnology · Similar size: $0 M revenue against $1 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $46 M (last known, Jul 30, 2023) · revenue $0 M (year to December 2025)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)+ Add
- ImageneBio, Inc.IMA · 🇺🇸 USASame industry: Biotechnology · Similar size: $1 M revenue against $1 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $50 M (Oct 27, 2026) · revenue $1 M (year to December 2025)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)+ Add
- Seres Therapeutics, Inc.MCRB · 🇺🇸 USASame industry: Biotechnology · Similar size: $1 M revenue against $1 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $20 M (Oct 30, 2026) · revenue $1 M (year to December 2025)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)+ Add
- Allarity Therapeutics, Inc.ALLR · 🇺🇸 USASame industry: Biotechnology · Similar size: $0 M revenue against $1 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $14 M (Oct 15, 2026) · revenue $0 M (year to December 2025)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)+ Add
GenVec: the market cap on file is more than 60 days old or a last known value (no market-data feed for its exchange yet), so its valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | GenVecbase GNVC · 🇺🇸 US Percentile in Healthcare Percentile in USA | Group median |
|---|---|---|
| Size | ||
| Revenue (Better neither way: ranked highest first) | $1 MFY2016 · SEConly one with it | $1 M— |
| Net income (Higher is better) | $-6 MFY2016 · SEConly one with it | $-6 M— |
| Employees (Better neither way: ranked highest first) | 15February 28, 2017 · Profileonly one with it | 15— |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = GenVec: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
Ranks need two fiscal years with the figure for at least two of these companies.
| Fiscal year | GenVec |
|---|---|
| 2016 | $1 MSEC |
| 2015 | $1 MSEC |
| 2014 | $6 MSEC |
| 2013 | $4 MSEC |
| 2012 | $9 MSEC |
| 2011 | $18 MSEC |
| 2010 | $16 MSEC |
| 2009 | $14 MSEC |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.